Aurobindo granted license for two HIV/AIDS antiretrovirals

By Lisa Kerner

Erie, Pa., March 17 - Aurobindo Pharma Ltd. said Bristol-Myers Squibb Co. has given it license to market two antiretrovirals, Stavudine and Didanosine, for the treatment of HIV/AIDS.

The license covers 49 countries including South Africa, according to a company news release.

Stavudine Capsules (30 mg and 40 mg) and Stavudine Oral Solution (1 mg/ml) are approved by the Food and Drug Administration and the Pepfar program.

Aurobindo, based in Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.